Table 2 Medicines consumption in the SES and the PPS
From: Comparison of two alternative study designs in assessment of medicines utilisation in neonates
| Â | SES | PPS | OR (95% CI) |
|---|---|---|---|
No of prescriptions during the study period | NA | 2608 | NA |
Median (IQR) No of prescriptions per neonate | NA | 2 (1;4) | NA |
No of active ingredients prescribed* | 313 | 280 | NA |
No of trade names (by name, manufacturer, pharmaceutical dosage form and strength) | 1065 | 624 | NA |
No of manufacturers | 332 | 235 | NA |
Route of administration (%) | |||
Parenteral | 58 | 59 | 0.96 (0.79-1.17) |
Enteral | 30 | 36 | 0.79 (0.64-0.97) |
Topical | 12 | 5 | 2.32 (1.57-3.42) |